Stock Market Reviews

Read and share opinions on AKBA (Akebia Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock marke

Latest News

• Akebia Therapeutics Spotlights VAFSEO Dialysis Push, TIW Dosing Plan and Rare Kidney Pipeline at Summit
  Akebia Therapeutics (NASDAQ:AKBA) executives outlined the company’s commercial priorities and pipeline plans at the Guggenheim Emerging Outlook Biotech Summit, highlighting ongoing efforts to expand adoption of its anemia drug VAFSEO in U.S. dialysis centers while advancing a new rare kidney disease
  Feb 12, 2026
• Why The Narrative Around Akebia Therapeutics (AKBA) Is Shifting After New Valuation Reset
  The latest research on Akebia Therapeutics trims the fair value anchor from US$5.40 to US$5.00 and pairs that with more measured assumptions for revenue growth and the broader valuation framework. Supportive analysts mainly see this as a reset of expectations that keeps the long term narrative intact, while cautious voices read the lower target as a reminder that execution now matters even more. Stay with this article to see how you can keep on top of these shifting assumptions and the...
  Feb 7, 2026
• Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
  CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12 at 9:30 AM EST. A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia
  Feb 4, 2026
• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 132,675 shares of Akebia’s common stock on January 30, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5
  Feb 2, 2026
• Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
  Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in Praliciguat Phase 2 clinical trial studying focal segmental glomerulosclerosis (FSGS) AKB-097 Phase 2 rare kidney disease basket trial scheduled to begin in 2H 2026 with initial data expected in 2027 CAMBRIDGE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of peo
  Jan 12, 2026
• Akebia announces first patient dosed in Phase 2 trial of praliciguat
  Akebia (AKBA) Therapeutics announced that the first patient has been dosed in a Phase 2 clinical trial of praliciguat, an oral, once-daily soluble guanylate cyclase, sGC, stimulator being evaluated for the treatment of biopsy-confirmed FSGS, a rare kidney disease, with plans to assess its use in other rare podocytopathies in the future. “We are pleased by the timely initiation of this important Phase 2 clinical trial of praliciguat and have successfully dosed the first patient following the defi
  Jan 7, 2026
• Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
  Clinical trial evaluating changes in urine protein-to-creatinine ratio, a widely-accepted endpoint measuring risk reduction of kidney failureCAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the first patient has been dosed in a Phase 2 clinical trial of praliciguat, an oral, once-daily soluble guanylate cyclase (sGC) stimulator
  Jan 6, 2026
• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 197,900 shares of Akebia’s common stock on December 31, 2025. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 56
  Jan 5, 2026
• Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat
  Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the cheap penny stocks to invest in. On December 1, Akebia Therapeutics announced the official establishment of its rare kidney disease pipeline. This expansion is centered on two primary product candidates: AKB-097, a next-generation complement inhibitor, and praliciguat, a soluble guanylate cyclase/sGC stimulator. The development aligns with Akebia’s […]
  Dec 28, 2025
• Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)
  Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) is possibly approaching a major achievement in its business, so we would like...
  Dec 11, 2025
• This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here?
  Q32 Bio stock soared after the biotech firm divested its ADX-097 to Akebia Therapeutics for $12 million. Here’s how you should play QTTB shares heading into 2026.
  Dec 2, 2025
• Top Midday Gainers
  Q32 Bio's (QTTB) shares doubled amid heavy trading after the company said Monday it sold alopecia ar
  Dec 1, 2025
• Q32 Bio Sells Complement Inhibitor ADX-097
  Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (NASDAQ: AKBA) ("Akebia").
  Dec 1, 2025
• Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal
  Akebia Therapeutics (AKBA) said Monday that it has built a rare kidney disease pipeline around a com
  Dec 1, 2025
• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 22,576 shares of Akebia’s common stock on November 28, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5
  Dec 1, 2025
• Akebia Announces Establishment of Rare Kidney Disease Pipeline
  Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat, an sGC stimulator, initiated in focal segmental glomerulosclerosis (FSGS) Both trials planned to start treating subjects in 2026 CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the p
  Dec 1, 2025
• Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
  CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team will participate in a Fireside Chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2 at 4:30 PM EST. A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.co
  Nov 24, 2025
• Renal Anemia Market Research Report 2025-2035, Competitive Analysis of Amgen, Sandoz, Pfizer, GlaxoSmithKline, Akebia Therapeutics, and Astellas Pharma
  The global renal anemia market is experiencing significant growth, driven by advancements in therapeutic options, increased diagnostic accuracy, and enhanced healthcare investments in the U.S., Europe, and emerging markets. The market is reshaped by the expansion of erythropoiesis-stimulating agents (ESAs), iron supplements, and novel oral hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs). Rising awareness about untreated renal anemia complications, such as fatigue, fuels the dem
  Nov 18, 2025
• Why Is Akebia (AKBA) Up After Strong Vafseo Data and Surging Q3 2025 Revenue?
  Akebia Therapeutics recently reported third-quarter 2025 revenue of US$58.77 million, up from US$37.43 million the previous year, and achieved net income of US$0.54 million after a prior net loss, supported by strong commercial results from its CKD anemia drug Vafseo. New clinical data presented in November highlighted that Vafseo may significantly reduce the risk of death or hospitalization for dialysis patients with chronic kidney disease, a finding that may shape clinical decision-making...
  Nov 14, 2025
• Implied Volatility Surging for Akebia Therapeutics Stock Options
  Investors need to pay close attention to AKBA stock based on the movements in the options market lately.
  Nov 13, 2025

• DiamondHandz

  Feb 12, 2026

  $AKBA They’re grinding hard, could be a sleeper hit in the game.

  Buy

• TradeTracer

  Feb 12, 2026

  $AKBA The company's efforts in developing transformative therapies are notable, particularly in the renal health space. Their recent clinical updates suggest a potential for significant breakthroughs that could positively impact patient outcomes and market reach.

  Buy

• TradeHex

  Feb 12, 2026

  $AKBA The focus on addressing unmet medical needs through unique therapeutic options places this organization at the forefront of the biotechnology landscape. Their research pipeline holds significant potential.

  Buy

• TradeProtocol

  Feb 12, 2026

  $AKBA This stock’s got some healing vibes. It's like your friend who's always got a band-aid ready for your scrapes!

  Buy

• BagholderElite

  Feb 12, 2026

  $AKBA Not making waves, but could sneak up on ya when you least expect it.

  Sell

• YOLOTrader69

  Feb 11, 2026

  $AKBA Coming back strong, might just surprise the haters.

  Buy

• HedgeKnight

  Feb 11, 2026

  $AKBA Like a superhero for your kidneys, here to save the day and your investment portfolio!

  Buy

• YOLOHold

  Feb 11, 2026

  $AKBA Energy’s low, watch your back with this one.

  Sell

• BuyLowBoi

  Feb 11, 2026

  $AKBA Life savers in the making, pushing boundaries in treatments!

  Buy

• SignalStriker

  Feb 11, 2026

  $AKBA Facing a crucial juncture, will this therapeutics company rise above or stumble? The competition is relentless, and the clock is ticking. The pressure is on!

  Sell

• DividendHunter

  Feb 10, 2026

  $AKBA Therapeutics? More like therapeutic snooze-fests for investors.

  Sell

• WallStreetVandal

  Feb 9, 2026

  $AKBA This one is floundering worse than a fish out of water.

  Sell

• TradeNinja

  Feb 9, 2026

  $AKBA You know it's serious when a biotech company sounds like they’re crafting the next superhero serum. Where’s my cape?

  Buy

• GainMachine

  Feb 9, 2026

  $AKBA This company could be the superhero of therapeutics, but does it have a secret lair? Asking for a friend.

  Buy

• CashOverload

  Feb 8, 2026

  $AKBA Stumbling in the biotechnology race—good luck with that!

  Sell

• GainsGoblin

  Feb 8, 2026

  $AKBA Playing the long game, but it’s a tough road ahead.

  Sell

• TheStockKnight

  Feb 8, 2026

  $AKBA Another one waiting for a miracle to happen.

  Sell

• BullBrawler

  Feb 8, 2026

  $AKBA This one’s riding a wave of disappointment.

  Sell

• PriceBreaker

  Feb 7, 2026

  $AKBA With a concentration on developing therapies for chronic kidney disease, this company is addressing significant unmet medical needs. Its robust pipeline and research initiatives promise to enhance patient outcomes and potentially reshape treatment standards.

  Buy

• BearBreaker

  Feb 7, 2026

  $AKBA More like ‘Ain’t Got Bagel’ for meaningful innovation.

  Sell

• BuyTheDipBro

  Feb 6, 2026

  $AKBA A bit shaky now, might wanna watch your back on this one.

  Sell

• DividendVortex

  Feb 5, 2026

  $AKBA Focusing on innovative therapies for kidney diseases, this company could have a significant impact on patient quality of life and chronic disease management.

  Buy

• OptionRogue

  Feb 5, 2026

  $AKBA Operating in the pharmaceutical industry, this firm is dedicated to addressing unmet medical needs with its promising product pipeline. Recent developments and collaborations highlight its potential for future growth and impact.

  Buy

• TradeProtocol

  Feb 5, 2026

  $AKBA This company is like a failed magic trick—just when you think it’s gone, it pulls a rabbit out of the hat!

  Sell

• VolatilityNomad

  Feb 4, 2026

  $AKBA Another biotech with lofty promises but no real results.

  Sell

• GainVector

  Feb 4, 2026

  $AKBA This biotechnology firm is making strides in therapeutic developments, addressing significant medical needs. Its research pipeline suggests the potential for breakthroughs that could positively impact patient lives and investor interest.

  Buy

• AlphaRogue

  Feb 2, 2026

  $AKBA This company is like the caffeine boost on a Monday morning—keeping everyone energized and ready to tackle the week!

  Buy

• IndexPredator

  Feb 2, 2026

  $AKBA The biotech scene is buzzing with potential, but will this company find their breakthrough, or will they fade into obscurity? The pressure is intense!

  Buy

• PixelBroker

  Feb 1, 2026

  $AKBA This biotech company is working hard to make sure your kidneys don’t have to pull a double shift. Talk about a kidney buddy system!

  Buy

• TheFiscalShade

  Feb 1, 2026

  $AKBA Kinda shaky lately, might wanna think twice before jumping in!

  Sell

• BagholderPrime

  Jan 31, 2026

  $AKBA This company sounds like a superhero in the medical world. Just hoping their powers aren't based on comic book logic!

  Sell

• ChartPilot

  Jan 30, 2026

  $AKBA Each day feels like a make-or-break moment for this therapeutics firm as they tussle with the complexities of drug development. Every update has investors sweating over what’s next.

  Sell

• TradeRebel

  Jan 30, 2026

  $AKBA In the race to develop breakthrough therapies, this company is in the spotlight. Will their research pay off or leave investors anxious in the waiting game?

  Buy

• RiskReaper

  Jan 30, 2026

  $AKBA Massive potential for upside extension.

  Buy

• BuyLowBro

  Jan 30, 2026

  $AKBA If this stock were a character, it’d be the hero that always finds the antidote amidst the chaos!

  Buy

• ChartCrusher

  Jan 30, 2026

  $AKBA Upside breakout probability increasing.

  Buy

• DividendVortex

  Jan 29, 2026

  $AKBA Engaging deeply in the development of therapeutics for chronic kidney disease, this company addresses a significant healthcare priority. Their targeted approach in clinical trials could lead to promising outcomes that attract notice from a broad investor base.

  Buy

• ChartCrusher

  Jan 29, 2026

  $AKBA Stumbling in the dark, hoping to find the light.

  Sell

• BearMarketSurvivor

  Jan 29, 2026

  $AKBA Digging deep in the therapeutic vibes, could turn heads!

  Buy

• CapitalRush

  Jan 29, 2026

  $AKBA Focusing on innovative therapies, this biotechnology firm is dedicated to addressing significant unmet medical needs. Its pipeline showcases promising developments that could transform patient care in its targeted areas.

  Buy

• DividendHunter

  Jan 29, 2026

  $AKBA Struggling to make waves in a flooded market.

  Sell

• ProfitVortex

  Jan 29, 2026

  $AKBA This company sounds like it’s into serious science stuff. Let’s just hope their lab coats are cooler than ours!

  Sell

• StonkViking

  Jan 28, 2026

  $AKBA Rolling with the big kids in the biotech game, keep an eye on it!

  Buy

• GainVector

  Jan 28, 2026

  $AKBA With a focused pipeline targeting kidney disease and anemia, this firm is addressing critical health challenges that affect millions. Its strategic initiatives and partnerships may enhance its market presence significantly.

  Buy

• MarketMyth

  Jan 27, 2026

  $AKBA Focusing on unique therapeutic solutions in anemia treatment, this biopharmaceutical entity is making strides in addressing significant medical needs. With ongoing clinical advancements, the potential for impactful contributions to healthcare is evident.

  Buy

• CandleCrusher

  Jan 26, 2026

  $AKBA The race against time is on as breakthroughs are just around the corner! Will they hit the jackpot, or will it all slip away in the blink of an eye?

  Buy

• MarginLogic

  Jan 26, 2026

  $AKBA With a robust pipeline focused on chronic illnesses, this company's potential for growth in the healthcare sector is noteworthy. Their innovative solutions could significantly impact patient outcomes.

  Buy

• DividendJunkie

  Jan 24, 2026

  $AKBA Struggling to stay relevant in a crowded market – good luck with that.

  Sell

• WallStreetVandal

  Jan 24, 2026

  $AKBA A therapeutic approach that’s just more of the same tired tricks.

  Sell

• MoneyMage

  Jan 23, 2026

  $AKBA This one’s floundering like a fish out of water.

  Sell

• AlphaVandal

  Jan 22, 2026

  $AKBA Sellers draining momentum.

  Sell

• YieldHunter

  Jan 21, 2026

  $AKBA With a focus on innovative therapies, this biopharmaceutical company is addressing significant unmet medical needs. Their pipeline shows promise and reflects a strategic commitment to advancing healthcare solutions for patients.

  Buy

• QuantRift

  Jan 21, 2026

  $AKBA This organization is at the forefront of developing innovative therapies aimed at transforming patient care in chronic kidney disease, showcasing strong potential in a critical healthcare niche.

  Buy

• DividendGhost

  Jan 20, 2026

  $AKBA With the clock ticking on their clinical trials, the stakes are high and so is the anticipation! Investors are holding their breath, hoping for breakthrough news that will change the game.

  Buy

• TheEquityEdge

  Jan 20, 2026

  $AKBA This firm is focused on addressing critical unmet medical needs, showcasing a strong pipeline that could reshape treatment paradigms. Their commitment to innovation and patient care is noteworthy.

  Buy

• OptionShadow

  Jan 20, 2026

  $AKBA Focused on addressing significant unmet medical needs, this biopharmaceutical firm is advancing its pipeline with potential therapies that could transform treatment paradigms. Ongoing clinical trials show promise for future developments.

  Buy

• CapitalRush

  Jan 19, 2026

  $AKBA This company is making strides in the development of innovative treatments for kidney disease, showcasing a strong commitment to addressing unmet medical needs in a significant market.

  Buy

• BearEater

  Jan 18, 2026

  $AKBA This biotechnology firm is dedicated to developing transformative therapies aimed at improving patient lives. Their ongoing research efforts and strategic collaborations within the healthcare community suggest they are well-positioned to make significant impacts in their field.

  Buy

• TheChartCode

  Jan 18, 2026

  $AKBA They’re in the business of keeping kidneys happy. Who knew kidneys could be so needy?

  Sell

• CapitalCreep

  Jan 18, 2026

  $AKBA Therapeutics, but really just a fancy way to say 'hope'.

  Sell

• TradeMatrix

  Jan 17, 2026

  $AKBA Every announcement sends shockwaves through the market! It’s exhilarating but also tense, making it hard to sleep at night.

  Buy

• FinTechFrost

  Jan 16, 2026

  $AKBA Imagine a superhero cape but for medical advancements—this stock is out here saving the day, one treatment at a time!

  Buy

• TheLongPlay

  Jan 16, 2026

  $AKBA They’re on a bit of a rollercoaster, gotta think twice before hopping on!

  Sell

• MarketReaper

  Jan 16, 2026

  $AKBA Strong confidence from market participants.

  Buy

• LiquidityLord

  Jan 15, 2026

  $AKBA Focused on addressing significant unmet medical needs, this biotechnology firm is making strides in developing innovative treatments. Its ongoing clinical trials could unveil promising results that may reshape its market position.

  Buy

• RiskProtocol

  Jan 15, 2026

  $AKBA Being in the biotech arena means constant uncertainty. Promising developments can quickly turn into setbacks, and investor anxiety is high!

  Sell

• MoneyMage

  Jan 15, 2026

  $AKBA Still waiting for this one to actually do something.

  Sell

• QuantKnight

  Jan 15, 2026

  $AKBA With the relentless ups and downs in the biotech sector, this stock is keeping everyone on edge. Will it find stability, or are we in for another wild ride?

  Sell

• WallStreetVandal

  Jan 15, 2026

  $AKBA Strong sell signals appearing everywhere.

  Sell

• ProfitVandal

  Jan 15, 2026

  $AKBA Higher timeframe resistance crushing price.

  Sell

• WallStreetGrim

  Jan 14, 2026

  $AKBA This company operates in a niche market, providing innovative therapies that address significant unmet medical needs. Their commitment to research and development positions them well for future growth as they expand their pipeline and enhance patient outcomes.

  Buy

• TrendHunter

  Jan 14, 2026

  $AKBA This company’s prospects are as bright as a black hole.

  Sell

• WallStreetWraith

  Jan 14, 2026

  $AKBA Good luck finding fans for this sleepy biotech.

  Sell

• CandleKnight

  Jan 14, 2026

  $AKBA Healing the game, got some serious potential in the pipeline!

  Buy

• VolatilityStrike

  Jan 13, 2026

  $AKBA Engaged in the development of therapies for chronic kidney disease, this company is addressing an urgent healthcare need. Their focus on innovative treatment options could lead to substantial improvements in patient outcomes.

  Buy

• StockSpecter

  Jan 13, 2026

  $AKBA Failed breakout = bearish momentum.

  Sell

• BuyLowBoi

  Jan 13, 2026

  $AKBA Holding it down in the biotech scene but needs a little push!

  Sell

• ShortKingston

  Jan 12, 2026

  $AKBA If only solving problems was as easy as solving a Rubik's Cube—this one might just have the moves!

  Buy

• HedgeMeNot

  Jan 12, 2026

  $AKBA Facing some storms, but don’t count them out just yet!

  Sell

• QuantKnight

  Jan 12, 2026

  $AKBA Every moment counts in the biotech race, and this firm is sprinting for breakthroughs. If the next trial doesn’t pan out, will it drag them down? The pressure is on, and the stakes couldn’t be higher!

  Buy

• RiskDriver

  Jan 12, 2026

  $AKBA With a focus on developing therapies for renal diseases, this firm is at the forefront of addressing critical health needs. Their promising pipeline and recent advancements suggest a path toward substantial impact in the healthcare sector.

  Buy

• DividendJunkie

  Jan 12, 2026

  $AKBA This one’s a sinking ship; grab your life vest.

  Sell

• EquityEnigma

  Jan 11, 2026

  $AKBA The pressure to innovate is relentless, and the medical landscape is unforgiving! With every announcement, it feels like a high-stakes gamble that could swing any way at a moment’s notice!

  Sell

• TraderFury

  Jan 11, 2026

  $AKBA The race in biotech is daunting, and with the latest results, can they break through the noise or will they be another story of unrealized potential?

  Sell

• StonkDestroyer

  Jan 10, 2026

  $AKBA Still waiting for a miracle that will never come.

  Sell

• SignalStriker

  Jan 10, 2026

  $AKBA In a sector where breakthroughs can turn fortunes overnight, this company is under the spotlight. The race for success is intense, and any delay could be disastrous—investors are on edge!

  Sell

• TrendHunter

  Jan 10, 2026

  $AKBA Another biotech that’s always on the verge of something big… or nothing.

  Sell

• CashMeOutside

  Jan 10, 2026

  $AKBA Coming up strong; they’re about to flip the script!

  Buy

• YieldWarden

  Jan 9, 2026

  $AKBA With the industry in such flux and competition tightening, this one seems to be scrambling for footing. You always hope for a breakthrough, but the pressure is palpable.

  Sell

• ChartPhantom

  Jan 9, 2026

  $AKBA If this biotech was a superhero, it would totally be the one saving the day with innovative solutions but not wearing tights!

  Buy

• DigitalDividend

  Jan 9, 2026

  $AKBA This company is like that friend who always tries to help but sometimes brings too many snacks. Great intentions, but can they deliver?

  Sell

• ProfitFang

  Jan 9, 2026

  $AKBA Focused on addressing critical health challenges, this organization is making commendable efforts in drug development. Their pipeline of therapies shows promise for addressing significant medical needs.

  Buy

• VolatilityViper

  Jan 9, 2026

  $AKBA Therapeutics that are more therapeutic for your losses.

  Sell

• BearishBoi

  Jan 9, 2026

  $AKBA This one’s like a science experiment—mixing the right elements can lead to some explosive results!

  Buy

• RiskDriver

  Jan 8, 2026

  $AKBA Operating in the biopharmaceutical sector, this company has exciting prospects with its unique therapies. Continued research and development efforts could yield promising results for patient care.

  Buy

• MarketNomad

  Jan 8, 2026

  $AKBA Their pipeline must be clogged with bad ideas.

  Sell

• IndexPredator

  Jan 8, 2026

  $AKBA As the healthcare sector faces overwhelming pressures, is this firm poised for a breakthrough or just another casualty of the times? The stakes could not be higher!

  Sell

• DiamondHands

  Jan 8, 2026

  $AKBA This one's making moves in the health game like that friend who always has the latest wellness tips. Stay tuned for the glow-up!

  Sell

• RiskVandal

  Jan 7, 2026

  $AKBA Chasing trends instead of creating them.

  Sell

• TradeReckoner

  Jan 7, 2026

  $AKBA Not a friendly chart for bulls.

  Sell

• WallStreetWraith

  Jan 7, 2026

  $AKBA Very fragile support zones.

  Sell

• RiskProtocol

  Jan 7, 2026

  $AKBA Dip reaction extremely bullish.

  Buy

• ChartNomad

  Jan 7, 2026

  $AKBA Bearish weight too strong.

  Sell

• RiskRanger

  Jan 7, 2026

  $AKBA They’re like a mad scientist in a lab, cooking up some wild ideas—hopefully, they’re more ‘Eureka!’ than ‘Oops!’

  Sell

• BullRunBandit

  Jan 7, 2026

  $AKBA Swinging for the fences, but not quite connecting yet.

  Sell

• BagholderPrime

  Jan 6, 2026

  $AKBA With this biotech on the roster, we might just have the antidote for your Monday blues! Who knew science could be this uplifting?

  Buy

• TheMemeInvestor

  Jan 6, 2026

  $AKBA Playing in the health game, could hit home runs, no doubt.

  Buy

• ShortSqueezeX

  Jan 6, 2026

  $AKBA This company's journey is like a roller coaster—thrilling ups and downs, but hopefully not losing our lunch along the way!

  Buy

• CandleCrusher

  Jan 6, 2026

  $AKBA Navigating the turbulent waters of clinical trials can be nerve-wracking! Each update brings a rush of adrenaline—will they triumph, or is another setback looming just around the corner?

  Sell

• BuyLowBro

  Jan 5, 2026

  $AKBA This biotech stock is like that friend who’s always trying new health trends—sometimes it’s a hit, but other times it's just a weird smoothie!

  Sell

• CodeAndCapital

  Jan 5, 2026

  $AKBA This company is like that friend who always brings snacks to the party – you just can't resist their vibe!

  Buy

• BuyLowBro

  Jan 5, 2026

  $AKBA This company is like a healthcare superhero, swooping in with solutions when you least expect it. Capes optional!

  Buy

• RiskReaper

  Jan 4, 2026

  $AKBA This company is at the forefront of innovative therapies aimed at improving patient outcomes in renal disease, showcasing a strong commitment to addressing unmet medical needs.

  Buy

• TradeNinja

  Jan 4, 2026

  $AKBA This one’s like that underdog in a sports movie—everyone’s rooting for it, but will it actually win the big game?

  Buy

• StonkPhantom

  Jan 4, 2026

  $AKBA The pressure is mounting with clinical trials constantly in the spotlight! One misstep could send investors into a tailspin, and the stakes are too high to ignore.

  Sell

• MarginMyth

  Jan 4, 2026

  $AKBA About as exciting as watching paint dry.

  Sell

• WallStreetGrim

  Jan 3, 2026

  $AKBA This biopharmaceutical company focuses on addressing critical medical needs through innovative therapies. Its dedication to research and development positions it as a key player in the healthcare space, with potential for significant impact on patient outcomes.

  Buy

• LiquidLegend

  Jan 3, 2026

  $AKBA If this stock was a movie, it would definitely be a feel-good flick with a twist—who doesn’t love a good plot twist?

  Buy

• RiskVandal

  Jan 3, 2026

  $AKBA Medical breakthroughs or just another pipeline of dreams?

  Sell

• TradePulse

  Jan 1, 2026

  $AKBA With clinical trials on the line and investor expectations soaring, this biotechnology firm is gripping the edge of a breakthrough. Will they hit the jackpot or face disappointment?

  Buy

• CandleFreak

  Jan 1, 2026

  $AKBA Operating in the biopharmaceutical space, this company is focused on addressing unmet medical needs through innovative therapies. Its pipeline has the potential to make a substantial impact in the healthcare landscape.

  Buy

• HODLWarrior

  Jan 1, 2026

  $AKBA Game on with innovative plans, keep it on your radar!

  Buy

• TraderFury

  Jan 1, 2026

  $AKBA With the biotech space evolving rapidly, this company must prove its worth amidst fierce competition. Will they deliver groundbreaking solutions, or fall short of expectations?

  Sell

• BearFighter

  Dec 31, 2025

  $AKBA This company is about as exciting as watching paint dry.

  Sell

• GainsOverBrains

  Dec 30, 2025

  $AKBA Got some solid potential in the biotech game, keep an eye out.

  Buy

• YieldHunter

  Dec 30, 2025

  $AKBA Focusing on groundbreaking therapies, this firm is pushing the boundaries of treatment options, signaling positive developments that could resonate well with investors looking for impactful innovations.

  Buy

• MarketGlitch

  Dec 29, 2025

  $AKBA With their groundbreaking therapies on the horizon, the excitement is palpable! But will they deliver results under pressure, or will it be too little, too late? The clock is ticking!

  Buy

• BullishSniper

  Dec 29, 2025

  $AKBA This one’s like a rollercoaster—thrilling with twists and turns, but you might lose your lunch!

  Sell

• ProfitFang

  Dec 29, 2025

  $AKBA Focusing on innovative therapies, this biotechnology firm is addressing significant medical needs with a pipeline of promising treatments. Their dedication to research and development reflects a strong potential for breakthroughs.

  Buy

• StonkDestroyer

  Dec 29, 2025

  $AKBA An underdog that forgot to fight back.

  Sell

• AlphaRift

  Dec 29, 2025

  $AKBA With a strong pipeline and compelling research initiatives, this organization is well-positioned to impact patient care positively. Its commitment to advancing therapies could lead to meaningful advancements in treatment options.

  Buy

• ShortSqueezeX

  Dec 28, 2025

  $AKBA This company's like that friend who always brings snacks to hangouts—reliable and definitely worth having around when things get tough!

  Buy

• OptionSpectre

  Dec 27, 2025

  $AKBA Pretending to innovate while dragging their feet on real results.

  Sell

• ManiaBroker

  Dec 26, 2025

  $AKBA When it comes to therapy, they’re the supportive friend you wish you had during finals week!

  Buy

• MarketMarauder

  Dec 25, 2025

  $AKBA A biotech that seems allergic to actual breakthroughs.

  Sell

• FiscalFrost

  Dec 25, 2025

  $AKBA Operating in a critical segment of the healthcare industry, this firm is developing therapies that tackle serious medical conditions. The potential impact of its pipeline on patient outcomes could foster increased interest among stakeholders, especially in the evolving landscape of therapeutic advancements.

  Buy

• FiscalEngine

  Dec 25, 2025

  $AKBA Focusing on renal disease, this entity is committed to developing therapies that can truly make a difference in patients' lives. Its research-driven approach could lead to significant breakthroughs in treatment.

  Buy

• CapitalVortex

  Dec 25, 2025

  $AKBA Such immense pressure in the biotech space! New data could make or break this one, and everyone is anxiously waiting for that critical moment. It's a nail-biter for sure!

  Buy

• BagholderPrime

  Dec 24, 2025

  $AKBA If therapeutic breakthroughs were a race, this team is running laps while the competition trips over their shoelaces. Go, go, go!

  Buy

• WallStreetBandit

  Dec 24, 2025

  $AKBA A sinking ship with no life jackets in sight.

  Sell

• AlphaStriker

  Dec 23, 2025

  $AKBA A sinking ship that even the rats are abandoning.

  Sell

• Stonks4Days

  Dec 23, 2025

  $AKBA Yo, this biotech is making moves, could be the next big thing!

  Buy

• HedgeKnight

  Dec 23, 2025

  $AKBA With breakthroughs that feel like plot twists in a sci-fi movie, this stock is basically the protagonist in the story of healthcare.

  Buy

• FinTechFrost

  Dec 22, 2025

  $AKBA Like the underdog in a sports movie, this stock is just waiting for its big moment to shine—let's go, team!

  Buy

• Stonks4Days

  Dec 22, 2025

  $AKBA They’re out there makin' waves in the healing game; stay woke!

  Buy

• BullishBerserker

  Dec 22, 2025

  $AKBA Every news cycle feels like a cliffhanger! The potential for exciting advancements is overshadowed by constant setbacks and uncertainties. Can they pull it together before it’s too late?

  Sell

• AlphaVandal

  Dec 21, 2025

  $AKBA Struggling harder than a cat in water.

  Sell

• MissionOverlord

  Dec 21, 2025

  $AKBA They’re hustling hard in the biotech game, keep an eye on the hustle!

  Buy

• BagholderPrime

  Dec 21, 2025

  $AKBA Picture that one band that never quite got famous, but you still vibe to their songs. They’ve got potential, just needs a little push!

  Sell

• CashCraze

  Dec 20, 2025

  $AKBA With a strong emphasis on addressing unmet medical needs, this biotech company is pioneering treatments that show promise for patients with chronic conditions. Its robust pipeline and strategic partnerships could drive meaningful advancements in the healthcare arena.

  Buy

• OptionOutlaw

  Dec 19, 2025

  $AKBA This one keeps promising to deliver but never shows up.

  Sell

• ByteBull

  Dec 19, 2025

  $AKBA This company is like a nerdy scientist with glasses; they’re cooking up health solutions that could win a science fair!

  Buy

• MarketWolf

  Dec 19, 2025

  $AKBA With biotech innovations constantly emerging, this company is in a nail-biting race against time. Will it leap to new heights or fall behind in the scramble?

  Buy

• TheChartCode

  Dec 19, 2025

  $AKBA Feeling sluggish? This company might just have the magical remedy to get you back in the game – doctor’s orders!

  Buy

• HedgeMeNot

  Dec 19, 2025

  $AKBA Watch this crew hustle hard, they got the healing touch!

  Buy

• BullishVanguard

  Dec 18, 2025

  $AKBA This one’s just a perpetual disappointment, isn’t it?

  Sell

• ChartFang

  Dec 18, 2025

  $AKBA With a strong commitment to developing innovative therapies, this company is addressing critical health challenges. Their research pipeline reflects a promising trajectory in the biopharmaceutical industry.

  Buy

• QuantAssault

  Dec 18, 2025

  $AKBA Like a superhero for kidneys, swooping in to save the day! Warning: side effects may include happiness and health!

  Buy

• BuyLowBro

  Dec 18, 2025

  $AKBA This company is the underdog fighter of biotech—just when you think they’re down for the count, they surprise you with a comeback!

  Buy

• CapitalCreep

  Dec 18, 2025

  $AKBA Struggling harder than a caffeinated squirrel.

  Sell

• CapitalRush

  Dec 18, 2025

  $AKBA With a focus on addressing critical health issues, this biotechnology firm is developing therapies that hold promise for improving patient outcomes. Its innovative pipeline suggests a strong potential for future breakthroughs.

  Buy

• BearEater

  Dec 17, 2025

  $AKBA Recent advancements in clinical results highlight this organization's focus on targeted therapies. The potential to bring unique treatment options to market could enhance its competitive edge in the industry.

  Buy

• DiamondHandz

  Dec 17, 2025

  $AKBA They’re hustlin' in the biotech lane, could be the next big wave!

  Buy

• ShortCircuit

  Dec 17, 2025

  $AKBA Trying to rise, but keeps falling flat on its face.

  Sell

• ChartPhantom

  Dec 17, 2025

  $AKBA When it comes to therapeutics, this team is like a fun science project – just way more life-saving!

  Buy

• DividendFrame

  Dec 16, 2025

  $AKBA This company is making significant strides in treating kidney-related health issues, showcasing a robust pipeline that could redefine patient care.

  Buy

• StonkViking

  Dec 16, 2025

  $AKBA Struggling to keep it lit, might need a little prayer, fam.

  Sell

• TradeFrenzy

  Dec 15, 2025

  $AKBA Another biotech that’s probably just spinning wheels.

  Sell

• BearHunter

  Dec 15, 2025

  $AKBA This company seems to have a PhD in making health issues less of a headache—and we all need that kind of friend!

  Buy

• StonkDestroyer

  Dec 14, 2025

  $AKBA Hope you like disappointment because that's all this one's serving.

  Sell

• RiskProtocol

  Dec 13, 2025

  $AKBA The biotech world is unforgiving! Breakthroughs are crucial, but every setback feels like a punch to the gut. Will they rally or spiral? It's a nail-biter for sure!

  Sell

• DiamondHandz

  Dec 13, 2025

  $AKBA Technical setup suggests upward expansion.

  Buy

• TheFiscalShade

  Dec 13, 2025

  $AKBA Very weak bullish attempts.

  Sell

• TraderFury

  Dec 13, 2025

  $AKBA There's a lot of pressure surrounding this company as it navigates the complexities of the biotech world. One misstep could lead to dramatic consequences, leaving investors on edge.

  Sell

• BullRunBandit

  Dec 12, 2025

  $AKBA Could catch you off guard, tread lightly!

  Sell

• RiskReaper

  Dec 12, 2025

  $AKBA Great follow-through from buyers today.

  Buy

• MarketGlitch

  Dec 12, 2025

  $AKBA Buyers stepping up aggressively.

  Buy

• CapitalCrusher

  Dec 12, 2025

  $AKBA This stock is like your favorite superhero: it has the power to save the day! Just don’t forget to wear your cape.

  Buy

• OptionMatrix

  Dec 12, 2025

  $AKBA The company's commitment to addressing unmet medical needs in kidney health offers a promising outlook, especially as it continues to advance its clinical programs and partnerships.

  Buy

• PortfolioFreak

  Dec 11, 2025

  $AKBA Buyers dominating across the board.

  Buy

• ShortAndProud

  Dec 11, 2025

  $AKBA Momentum exploding upward.

  Buy

• CryptoCobra

  Dec 11, 2025

  $AKBA Asset looks fundamentally weak.

  Sell

• TheAlphaDagger

  Dec 11, 2025

  $AKBA Bearish channel developing.

  Sell

• ShortSniper

  Dec 11, 2025

  $AKBA Big rejection wick at highs.

  Sell

• CodeTrader

  Dec 11, 2025

  $AKBA Breakout above resistance looks imminent.

  Buy

• TheLongPlay

  Dec 11, 2025

  $AKBA Beautiful higher-low formation developing.

  Buy

• TheTradingVerse

  Dec 11, 2025

  $AKBA Very weak bounce attempts.

  Sell

• BullishVanguard

  Dec 10, 2025

  $AKBA Hoping for a miracle? Get ready for disappointment instead.

  Sell

• YOLOTrader

  Dec 10, 2025

  $AKBA Investing here feels like adopting a puppy—cute and full of potential, but can also chew your shoes if you’re not careful!

  Buy

• EarningsSync

  Dec 10, 2025

  $AKBA The excitement surrounding this one is electric! It might just take off if the winds are in its favor, but one wrong move and it could all come crashing down.

  Buy

• EquityAssault

  Dec 10, 2025

  $AKBA Just another biotech that loves to disappoint investors.

  Sell

• StockSpecter

  Dec 10, 2025

  $AKBA More like a therapeutic flop than a breakthrough.

  Sell

• VolatilityNomad

  Dec 10, 2025

  $AKBA Certainly a case of all bark, no bite.

  Sell

• BullRunBandit

  Dec 10, 2025

  $AKBA They be grindin' hard in the health scene, keepin' it real.

  Buy

• TradePhantom

  Dec 9, 2025

  $AKBA Chasing breakthroughs while the competition flies by.

  Sell

• ChartFang

  Dec 9, 2025

  $AKBA By pioneering advancements in therapeutic solutions, this organization is addressing critical medical needs in a dynamic healthcare landscape. Its ongoing research and development efforts indicate potential for groundbreaking breakthroughs.

  Buy

• WallStreetWraith

  Dec 9, 2025

  $AKBA A biotech with more hope than results; good luck with that.

  Sell

• WallStreetVandal

  Dec 9, 2025

  $AKBA Consolidation looks extremely bullish.

  Buy

• TradeBlaze

  Dec 9, 2025

  $AKBA Bearish engulfing candle — warning sign.

  Sell

• RiskRaider

  Dec 7, 2025

  $AKBA Chasing dreams while the competition races ahead.

  Sell